Befejeződött1. fázis
A Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of Ascending Intravenous Doses of Glofitamab, Administered after Ocrelizumab Pretreatment, in Patients with Multiple Sclerosis
Key facts
- Where
- Grad Zagreb, HorvátországSee the 2 sites
- Phase
- 1. fázis
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Horvátország
- KBC ZagrebGrad Zagreb, HorvátországNo longer taking part
- Klinicki bolnicki centar Sestre milosrdniceGrad Zagreb, HorvátországNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- F. Hoffmann-La Roche AG
- Trial code
- EU 2023-506863-32-00
- Record updated
- 2025. szeptember 3.